Increased integration and synergy in EEG- and fNIRS-based data in migraine patients after a three-month treatment with galcanezumab: relations with long-term clinical outcome
Abstract Galcanezumab is a well-tolerated monoclonal antibody developed for migraine prophylaxis. Although its action mechanisms are not fully understood, they may involve changes in cortical connectivity. This study explores galcanezumab-induced central changes by investigating metabolic-electrical...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Portfolio
2025-12-01
|
| Serija: | Scientific Reports |
| Teme: | |
| Online pristup: | https://doi.org/10.1038/s41598-025-30274-0 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
